RAS-dependent RAF-MAPK hyperactivation by pathogenic RIT1 is a therapeutic target in Noonan syndrome–associated cardiac hypertrophy
Science Advances · 14.07.2023 · 9 (28)
DOI: 10.1126/sciadv.adf4766 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 14.07.2023. Verfasst von Antonio Cuevas-Navarro und 14 weiteren Autor:innen. Beteiligte Einrichtung: Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA. Hauptthemen laut MEDLINE: Noonan Syndrome, Lung Neoplasms. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
RIT1 is a RAS guanosine triphosphatase (GTPase) that regulates different aspects of signal transduction and is mutated in lung cancer, leukemia, and in the germline of individuals with Noonan syndrome. Pathogenic RIT1 proteins promote mitogen-activated protein kinase (MAPK) hyperactivation; however, this mechanism remains poorly understood. Here, we show that RAF kinases are direct effectors of membrane-bound mutant RIT1 necessary for MAPK activation. We identify critical residues in RIT1 that facilitate interaction with membrane lipids and show that these are necessary for association with RAF kinases and MAPK activation. Although mutant RIT1 binds to RAF kinases directly, it fails to activate MAPK signaling in the absence of classical RAS proteins. Consistent with aberrant RAF/MAPK activation as a driver of disease, we show that pathway inhibition alleviates cardiac hypertrophy in a mouse model of RIT1 mutant Noonan syndrome. These data shed light on the function of pathogenic RIT1 and identify avenues for therapeutic intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA.
- NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD 21702, USA.
- Department of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY 10016, USA.
ORCID-Profile: Antonio Cuevas-Navarro, Morgan Wagner, Stephanie Mo, Madeline R Allison, Simon Messing, Thomas J Turbyville, Dhirendra K Simanshu, Matthew J Sale, Frank McCormick, Andrew G Stephen, Pau Castel
Förderung
- NCI NIH HHS
Zitieren
APA
Cuevas-Navarro, A., Wagner, M., Van, R., Swain, M., Mo, S., Columbus, J., Allison, M. R., Cheng, A., Messing, S., Turbyville, T. J., Simanshu, D. K., Sale, M. J., McCormick, F., Stephen, A. G., & Castel, P. (2023). RAS-dependent RAF-MAPK hyperactivation by pathogenic RIT1 is a therapeutic target in Noonan syndrome–associated cardiac hypertrophy. Science Advances, 9(28). https://doi.org/10.1126/sciadv.adf4766
Vancouver
Cuevas-Navarro A, Wagner M, Van R, Swain M, Mo S, Columbus J, et al. RAS-dependent RAF-MAPK hyperactivation by pathogenic RIT1 is a therapeutic target in Noonan syndrome–associated cardiac hypertrophy. Science Advances. 2023;9(28). doi:10.1126/sciadv.adf4766
BibTeX
@article{CuevasNavarro2023,
author = {Cuevas-Navarro, Antonio and Wagner, Morgan and Van, Richard and Swain, Monalisa and Mo, Stephanie and Columbus, John and Allison, Madeline R and Cheng, Alice and Messing, Simon and Turbyville, Thomas J and Simanshu, Dhirendra K and Sale, Matthew J and McCormick, Frank and Stephen, Andrew G and Castel, Pau},
title = {RAS-dependent RAF-MAPK hyperactivation by pathogenic RIT1 is a therapeutic target in Noonan syndrome–associated cardiac hypertrophy},
journal = {Science Advances},
year = {2023},
volume = {9},
number = {28},
doi = {10.1126/sciadv.adf4766}
}
EUVIMED